Navigation Links
Final countdown: Atlantis to carry next-generation vaccine candidate on last space voyage
Date:7/6/2011

is approach is being applied to Salmonella vaccines. Because RASVs can be produced against a wide variety of human and animal pathogens, the outcome of this research could influence the development of vaccines against many other diseases in addition to pneumonia

Unlike existing anti-pneumococcal vaccines, Curtiss' RASV may be given orally and acts to stimulate mucosal, humoral and cellular immunity, offering enhanced protection. Diseases due to Streptococcus pneumoniae include community-acquired pneumonia, otitis media, meningitis, and bacteremia, and are responsible for some 10 million fatalities per year. Pneumonia poses a particular threat to newborns and the elderly, who may fail to mount an effective immune response after receiving current anti-pneumococcal vaccines.

The current experiments planned for Atlantis' final mission represent an interesting twist in Nickerson's research into microbial virulence and modes of infection, which she has pursued with longtime collaborator Mark Ott, a senior microbiologist at the Johnson Space Center and a Co-Investigator on the RASV flight experiment. Again, the pathogen of choice is Salmonella, but here, the invader has been genetically re-engineered to protect from infectious disease, rather than to cause it. The outcome of this research has the potential for better protecting astronauts, who are keenly vulnerable to infection during spaceflight, as well as to help engineer better therapeutics for infectious diseases on earth.

Specially designed growth chambers containing the vaccine strain will travel with Shuttle Atlantis to the International Space Station. During spaceflight, crewmembers will activate the samples, while simultaneously, an earthbound sample will be grown under otherwise identical conditions. The spaceflight cultured RASV strain, upon its return, will be evaluated against the control sample and analyzed for its ability to protect against pneumococcal
'/>"/>

Contact: Joseph Caspermeyer
Joseph.Caspermeyer@asu.edu
Arizona State University
Source:Eurekalert  

Page: 1 2 3 4

Related biology technology :

1. SCOLR Pharma, Inc. Announces Final Closing of Private Placement
2. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
3. TEI Biosciences Chairman, President and CEO Yiannis Monovoukas Named Ernst & Young Entrepreneur Of The Year® 2011 New England Award Semifinalist
4. Mtech Announces Semifinalists for University of Maryland $75K Business Plan Competition
5. Helix BioPharma Completes Definitive GLP Toxicology Studies With L-DOS47 and is Making Final Preparations for its Planned Phase I/II Clinical Study IND/CTA Submissions
6. Dyadic International Announces Final Resolution and Dismissal of Stockholder Class Action Lawsuit
7. Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010
8. Alexandria Real Estate Equities, Inc. Receives Final Approval From City of Cambridge to Develop Its East Cambridge State-of-the-Art Life Science Community
9. ChemoCentryx President and CEO, Thomas J. Schall, Ph.D., Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist in Northern California
10. ViroPharma Announces Availability of Cinryze(TM) (C1 Esterase Inhibitor [Human]) Final Open-Label Data
11. Profil Institutes Dr. Marcus Hompesch Named Finalist in Ernst & Young Entrepreneur Of The Year(R) 2010 Award for Second Year in a Row
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Final countdown: Atlantis to carry next-generation vaccine candidate on last space voyage
(Date:4/30/2015)... MN , April 30, 2015 /PRNewswire/ - BioAmber ... producing sustainable chemicals, today announced that it has commenced an ... BioAmber expects to grant the underwriters a 30-day option ... the shares of common stock offered in the public ... there can be no assurance as to whether or ...
(Date:4/30/2015)... The following is an open letter sent April ... Blood Corp (NYSE: CO ) from Jayhawk Capital. ... directors of China Cord Blood Corp (" China Cord ") ... share from Golden Meditech Holdings Co Ltd ("Golden Med"). Certainly, ... benefit Golden Med and Mr. Kam, the Chairman of both ...
(Date:4/30/2015)... , April 30, 2015  Pfenex Inc. (NYSE ... the development of biosimilar therapeutics including high value ... closing of its previously announced underwritten public offering ... a public offering price of $15.50 per share. ... underwriters of their option to purchase up to ...
(Date:4/30/2015)... 30, 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" ... global contract R&D services provider, today announced that its ... letter, dated April 29, 2015, from a consortium (the ... "Chairman"), founder, chairman and chief executive officer of the ... proposes a transaction (the "Transaction") involving the acquisition of ...
Breaking Biology Technology:BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6
... May 13 Xennex, Inc. (Xennex) announced today ... of Version 3.0 beta, available at ... 3.0 features a significantly upgraded infrastructure, including a ... and speedier search engine. It provides capabilities for ...
... OF INDUSTRY, Calif. and HONG KONG, May 13 ... that its 49% owned subsidiary, Excalibur International Marine Corporation, ... Taiwan Strait between Taiwan and Mainland China. Excalibur,s ... and is capable of carrying over 300 tons of ...
... DIEGO, May 12 Amylin Pharmaceuticals, Inc. (Nasdaq: ... Care Conference on Tuesday, May 19, 2009 at ... Daniel M. Bradbury, president and chief executive officer of Amylin ... session will be webcast, and a recording will be made ...
Cached Biology Technology:GeneCards(R) Version 3.0 Beta Released 2GeneCards(R) Version 3.0 Beta Released 3EFT BioTech Holdings, Inc.'s Subsidiary Receives First Permit to Cross Taiwan Strait 2EFT BioTech Holdings, Inc.'s Subsidiary Receives First Permit to Cross Taiwan Strait 3
(Date:4/1/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces the second shipment ... underway to early access pre-order customers. ... retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop ... accepted at all outlets and very easy to use. ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
(Date:3/24/2015)... --  NexID Biometrics LLC, whose spoof-mitigation technology boosts ... the beginning of shipments of version 2.0 of its ... based in Potsdam, N.Y. , is ... began here today at the Walter E. Washington Convention ... SDK boosts the accuracy rate range to 96.5 to ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... TORONTO A study led by scientists at The ... identifying drugs to treat children suffering from fatal cancers for ... developing a new drug from scratch, which is a complicated ... lab, they tested existing drugs on cancer stem cells from ...
... at Montana State University have developed six new biomedical ... infections, fungal infections and viral infections; boosting humans, innate ... The technologies are available for licensing to ... involves an existing clinical drug that was discovered to ...
... Market - Advanced Technologies, Global Forecast and Winning Imperatives... -- DALLAS, August 18, 2010 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Biology News:Scientists find new twist on drug screening to treat common childhood cancer 2Scientists find new twist on drug screening to treat common childhood cancer 3Montana State University offers 6 new biomedical technologies for licensing 2Montana State University offers 6 new biomedical technologies for licensing 3Montana State University offers 6 new biomedical technologies for licensing 4New Report - Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014) By MarketsandMarkets 2New Report - Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014) By MarketsandMarkets 3New Report - Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014) By MarketsandMarkets 4New Report - Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014) By MarketsandMarkets 5New Report - Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014) By MarketsandMarkets 6New Report - Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014) By MarketsandMarkets 7
... for interferons are cytopathic effect inhibition assays, also ... types include; tissue culture supernatents; serum from PK ... one unit is defined as the quantity of ... effect of viral infection by 50%. ...
... cytopathic effect inhibition assays, also known as CPE ... culture supernatents; serum from PK studies and delivery ... defined as the quantity of interferon required per ... infection by 50%. All standards used ...
... effect inhibition assays, also known as CPE and ... supernatents; serum from PK studies and delivery formulations. ... as the quantity of interferon required per milliliter ... by 50%. All standards used in ...
Request Info...
Biology Products: